SCHEMBL611007

SCHEMBL611007

CCCCNC(N)=NO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24115232 1.00
SCHEMBL10339979 1.00
SCHEMBL627214 0.93 GRIN2D (0.55)
SCHEMBL11215506 0.81
SCHEMBL9059809 0.81
SCHEMBL17196964 0.81
SCHEMBL15787136 0.80 CYP2C19 (0.48)
SCHEMBL9059098 0.79 GRIN2D (0.73)
SCHEMBL1276676 0.77 GRIN2D (1.00)
SCHEMBL13181225 0.76 GRIN2D (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008157537-A2 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC (US) 2008-12-24 WO claimed
WO-2008124505-A2 SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS,INC. (US) 2008-10-16 WO claimed
JP-2295961-A None JP disclosed
US-20260116886-A1 DEUTERATED sGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2026-04-30 US disclosed
US-20260000653-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2026-01-01 US disclosed
US-20250326761-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2025-10-23 US disclosed
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20250243205-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2025-07-31 US disclosed
US-20250243177-A1 sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2025-07-31 US disclosed
US-20250243228-A1 PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2025-07-31 US disclosed
US-20250129060-A1 SOLID FORMS OF AN SGC STIMULATOR CYCLERION THERAPEUTICS INC (US) 2025-04-24 US disclosed
US-20120040025-A9 Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention IRONWOOD PHARMACEUTICALS, INC. 2012-02-16 US disclosed
WO-2011115804-A1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2011-09-22 WO disclosed
US-20110160225-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-30 US disclosed
US-20100215779-A1 Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention IRONWOOD PHARMACEUTICALS, INC. 2010-08-26 US disclosed
US-20100144864-A1 SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2010-06-10 US disclosed
EP-2152266-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION Ironwood Pharmaceuticals, Inc. (US) 2010-02-17 EP disclosed
US-20090054450-A1 COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed
WO-2008137318-A1 COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION IRONWOOD PHARMACEUTICALS, INC. (US) 2008-11-13 WO disclosed
JP-H02295961-A GUANIDINE DERIVATIVE, PRODUCTION THEREOF AND INSECTICIDE AND ACARICIDE NIPPON SODA CO LTD 1990-12-06 JP disclosed